INT2607

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.30
First Reported 1979
Last Reported 1983
Negated 0
Speculated 0
Reported most in Abstract
Documents 3
Total Number 5
Disease Relevance 1.52
Pain Relevance 0.88

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (NEU1) hydrolase activity, acting on glycosyl bonds (NEU1) cytoplasmic membrane-bounded vesicle (NEU1)
plasma membrane (NEU1) lysosome (NEU1)
Anatomy Link Frequency
PMNs 6
lymphocytes 2
NEU1 (Homo sapiens)
Pain Link Frequency Relevance Heat
aspirin 4 94.66 High High
cINOD 4 93.76 High High
Inflammation 3 83.28 Quite High
Arthritis 1 82.36 Quite High
Analgesic 1 80.32 Quite High
rheumatoid arthritis 1 75.52 Quite High
Osteoarthritis 1 73.76 Quite High
Pain 1 68.96 Quite High
Disease Link Frequency Relevance Heat
Agranulocytosis 1 99.40 Very High Very High Very High
Neutropenia 2 97.16 Very High Very High Very High
INFLAMMATION 10 95.44 Very High Very High Very High
Disease 1 83.64 Quite High
Arthritis 1 82.36 Quite High
Rheumatoid Arthritis 1 75.52 Quite High
Osteoarthritis 1 73.76 Quite High
Crystal Associated Disease 1 72.48 Quite High
Pain 1 68.96 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In vitro, piroxicam inhibits both superoxide anion production and lysosomal enzyme release from human neutrophils and also inhibits IgM-rheumatoid factor production by human lymphocytes.
Negative_regulation (inhibits) of Localization (release) of lysosomal enzyme in lymphocytes
1) Confidence 0.30 Published 1983 Journal Eur J Rheumatol Inflamm Section Abstract Doc Link 6345166 Disease Relevance 0.72 Pain Relevance 0.31
In contrast, the non-steroidal anti-inflammatory drugs (indomethacin, meclofenamic acid and aspirin), which only block the cyclo-oxygenase pathway of AA metabolism, had little effect on enzyme release from PMNs induced by the same stimuli. 5,8,11-Eicosatriynoic acid (ETI), a selective inhibitor of the lipoxygenase pathway of AA metabolism, caused a dose-dependent inhibition of lysosomal enzyme release elicited by Zx, f-met peptide, and A23187. p-Bromophenacyl bromide (BPB), which inhibits the phospholipase A2 (PLA2) activity in several tissues, was found to cause a dose-dependent inhibition of lysosomal enzyme release induced by the same immunological and non-immunological stimuli.
Negative_regulation (inhibition) of Localization (release) of lysosomal enzyme in PMNs associated with aspirin, inflammation and cinod
2) Confidence 0.10 Published 1983 Journal J Clin Lab Immunol Section Abstract Doc Link 6644791 Disease Relevance 0.09 Pain Relevance 0.14
In contrast, the non-steroidal anti-inflammatory drugs (indomethacin, meclofenamic acid and aspirin), which only block the cyclo-oxygenase pathway of AA metabolism, had little effect on enzyme release from PMNs induced by the same stimuli. 5,8,11-Eicosatriynoic acid (ETI), a selective inhibitor of the lipoxygenase pathway of AA metabolism, caused a dose-dependent inhibition of lysosomal enzyme release elicited by Zx, f-met peptide, and A23187. p-Bromophenacyl bromide (BPB), which inhibits the phospholipase A2 (PLA2) activity in several tissues, was found to cause a dose-dependent inhibition of lysosomal enzyme release induced by the same immunological and non-immunological stimuli.
Negative_regulation (inhibition) of Localization (release) of lysosomal enzyme in PMNs associated with aspirin, inflammation and cinod
3) Confidence 0.10 Published 1983 Journal J Clin Lab Immunol Section Abstract Doc Link 6644791 Disease Relevance 0.09 Pain Relevance 0.13
We have studied the role of arachidonic acid (AA) metabolism in the release of lysosomal enzymes (beta-glucuronidase and lysozyme) from human polymorphonuclear leukocytes (PMNs). 5,8,11,14-Eicosatetraenoic acid (ETYA), which inhibits both the cyclo-oxygenase and the lipoxygenase pathways of AA metabolism, was found to cause a dose-dependent inhibition of lysosomal enzyme release from human PMNs induced by immunological (i.e., serum-treated zymosan: Zx) and nonimmunological stimuli (i.e., formyl methionine-containing peptide and the Ca2+ ionophore A23187).
Negative_regulation (inhibition) of Localization (release) of lysosomal enzyme in PMNs
4) Confidence 0.10 Published 1983 Journal J Clin Lab Immunol Section Abstract Doc Link 6644791 Disease Relevance 0.08 Pain Relevance 0.12
P and S also abrogated adherence-induced lysosomal enzyme release and FP-stimulated hexose monophosphate pathway (HMP) activity.
Negative_regulation (abrogated) of Localization (release) of lysosomal enzyme
5) Confidence 0.01 Published 1979 Journal Schweiz Med Wochenschr Section Abstract Doc Link 482916 Disease Relevance 0.53 Pain Relevance 0.18

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox